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SIGNIFICANCE STATEMENT
The precise regulation of Th17 cell metabolic function is central to an inflammatory response.
Following activation, T cells undergo metabolic reprogramming and utilise up-regulated glycolysis to increase the availability of ATP. This work establishes an epigenetic link between the H3K27 demethylases KDM6A/B and the coordination of a metabolic response in activated Th17 cells.
Inhibition of KDM6A/B leads to global increases in the repressive H3K27me3 histone mark resulting in down-regulation of key transcription factors, followed by metabolic reprogramming and the induction of anergy in Th17 cells. This work suggests a critical role of KDM6 enzymes in maintaining Th17 functions by controlling metabolic switches, necessary for T cells to adapt to their specific roles. including T helper 1 (Th1), Th2 and Th17, characterised by different cytokine profiles and effector functions (1). In addition to their role as potent inducers of tissue inflammation, Th17 cells also serve physiological roles in host defence against bacterial or fungal infections and provide key roles in maintaining tissue barrier homeostasis (2) (3) (4) (5) . Transforming growth factor beta (TGF-β) and
interleukin 6 (IL-6) are cytokines pivotal in the initial commitment of naïve T-cells towards the Th17 lineage (6-8), supported by other cytokines such as IL-23, IL-21 and IL-1β, involved in the expansion, stability and function of Th17 cells (9-11). The master transcriptional regulator RARrelated orphan receptor gamma (RORγt) is necessary to coordinate the Th17 commitment and promotes IL-17 expression (12) . A loss or inhibition of RORγt can block Th17 differentiation in vitro and is inhibitory in models of autoimmune encephalomyelitis, imiquimod-induced cutaneous inflammation and collagen-induced arthritis (13) (14) (15) .
The critical role of epigenome and chromatin modifications in differentiation and commitment from naïve T cells to T helper subsets has been demonstrated (16, 17) . Chromatin templated posttranslational modifications control gene transcription, DNA replication and repair, resulting in the concept of a chromatin or "histone code" that determines distinct cell states (18) . In this context histone methylation plays a fundamental role in the maintenance of both active and suppressed states of gene expression, depending on the sites and degree of methylation (19) . The trithorax and polycomb paradigms in particular, identified in Drosophila genetics, are centered around trimethylation of histone H3 at lysine residues -4, (H3K4me3) which is implicated in the activation of transcription, and methylation of histone H3 at lysine -27 (H3K27me3), which is correlated with repression of transcription. The reversibility and dynamic behaviour of H3K27 methylation is provided by the methyltransferase enhancer of zeste homolog 2 (EZH2) and by several members of the Jumonji domain containing (Jmj) Fe2+ and 2-oxoglutarate dependent oxygenases, which catalyse demethylation of methylated histone lysine residues in vitro and in vivo. In particular, Jmj family members 3 (JMJD3, KDM6B) and Ubiquitously transcribed Tetratricopeptide repeat gene, X chromosome, (UTX, KDM6A) were shown to be specific demethylases of H3K27me2/3. H3K27me3 histone marks has revealed that chromatin modifications also contribute to the specificity and plasticity of effector Th17 cells, and provides a framework for using global epigenomic analyses to understand the complexity of T helper cell differentiation (24) .
Subsequently, chemical screening using inhibitors against various components of the epigenetic machinery has revealed novel epigenetic pathways that regulate Th17 effector function. These include the BET bromodomains, the CBP/p300 bromodomain and the KDM6A/KDM6B Jumonji histone demethylases, able to regulate CD4+ differentiation or Th17 function in vitro (25) (26) (27) (28) .
Metabolic pathways are intimately linked with epigenetics, transcriptional regulation and modulate cell fate and function (29) (30) (31) (32) . Moreover, targeting metabolic pathways with small molecules in autoimmunity may be a beneficial strategy for the treatment of Th17-mediated disease, such as Ankylosing Spondylitis (AS). For example, it has been reported that metabolic reprogramming using the small molecule aminooxy-acetic acid is sufficient to shift the differentiation of Th17 cells towards an inducible regulatory T cell (iTreg) phenotype, involving accumulation of 2-hydroxyglutarate, leading to hypomethylation of the gene locus of the key Treg transcription factor foxp3 (33).
Here we establish a novel link between the H3K27 demethylases KDM6A and KDM6B in regulating Th17 cell metabolism. We show that KDM6A and KDM6B demethylases are key factors in regulating the Th17 pro-inflammatory phenotype, and control metabolic function and differentiation into effector cells. Inhibiting these enzymes results in a global increase in H3K27me3 with consequential metabolic reprogramming that leads to the emergence of an anergic phenotype.
RESULTS

Inhibitor screening identifies histone H3K27 demethylases as key regulators of pro-
inflammatory effector T cell phenotypes -Using a focused library of small molecule inhibitors (SI Appendix) that target eight major classes of chromatin and epigenetic proteins, we measured the expression of Th cytokines following 24 hours of treatment of in vitro differentiated CD4+ cells. We evaluated the expression of IFN-γ, IL-4 and IL-17 as markers for Th1, Th2 and Th17 cells, respectively ( Figure 1A) . A consistent downregulation of cytokine expression following treatment with inhibitors against the JmjC-domain containing histone demethylases (KDM6A/KDM6B), bromodomains and histone deacetylases (HDACs) was observed in all effector subsets (Figure 1A , Figure S1A ), suggesting a common epigenetic susceptibility. Given the importance of H3K27 (KDM6) demethylases in cellular development (34, 35) and inflammation (36), we focused this study towards the prototypic KDM6 inhibitor GSK-J4 (37), displaying an EC 50 of 2μM ( Figure S1B) , and its inactive regional isomer GSK-J5 as a control. Using two different Th17 differentiation models, in which either CD4 + or CD45RA + cells are cultured in a cocktail of IL-6, IL-23 and TGF-β cytokines for 7 days, followed by treatment with DMSO, GSK-J4 or GSK-J5 for 48 hours, we observed a significant reduction in IL-17 and IFN-γ (Figure 1B, Figure S2A ) by GSK-J4, with constant levels of
RORC expression ( Figure S2A) . In contrast, addition of GSK-J4 during the differentiation process led to reduced cytokine production ( Figure S2B, S2C) , with a significant reduction in the expression of RORC (Figure S2C) , indicating that this Th17 master transcription factor requires KDM6 demethylase activity during differentiation and not in the effector state.
Histone demethylases KDM6A and KDM6B regulate Th17 cell maturation -We observed a decrease in the activation of Th17 cells, as measured by CD25 and CCR4 flow cytometry staining, following culture in the presence of GSK-J4 (Figure S2D and S2E) . No increase in cell death was measured following 48 hours of GSK-J4 treatment, as measured by propidium iodide and Annexin-V staining (Figure S2F) . GSK-J4 is a cell-permeable and potent selective inhibitor of KDM6 demethylases and has ~5-20-fold lower activity against KDM5B demethylating enzymes in vitro (37, 38) . In order to assess the specificity of GSK-J4 and evaluate the contribution of each KDM enzyme to Th17 function, we used locked nucleic acid (LNA) knockdown of KDM6A/B and the potential GSK-J4 off-target, KDM5B (JARID1B) ( Figure 1C ). Knockdown of KDM6A and KDM6B, either against single or simultaneously against both targets, led to reduced levels of IL-17 and IFN-γ ( Figure 1D, Figure S3A, S3B) . Moreover, knockdown of KDM6A and KDM6B also impacted on the proliferation of Th17 cells, as measured by cell counting (Figure 1E) , whereas KDM5B knockdown has a lesser impact on these phenotypes. The results corroborate the role for Jumonji histone demethylase activity regulating the pro-inflammatory function and proliferation of Th17 cells (28, 39) and confirm the previously noted KDM6A/B on-target activity of the GSK-J4 chemical tool compound (37).
KDM6 inhibitor treatment suppresses pro-inflammatory cytokine production and
proliferation in autoimmune patient cells -It was of interest to validate the earlier antiinflammatory observations within a context of chronic inflammation. Consistent with our earlier work on chronic inflammation in NK cells (36), we observe IFN-γ reduction in GSK-J4 treated CD3 + T cells isolated from Rheumatoid Arthritis (RA) patients (Figure 2A) , and also of IL-17 in AS patients ( Figure 2B) . A significant reduction in the proportion of cells in G2/M phase (Figure 2C) , associated with reduced Th17 proliferation following treatment with GSK-J4 ( Figure 2D ) was observed. The reversible nature of the GSK-J4 effect is demonstrated in washout experiments, where cells were treated for 48 hours with the inhibitor, followed by media change after 24 hours when GSK-J4 was omitted. After 48 hours cells partially regained their ability to secrete cytokines (Figure 2E ). Single cell profiling using mass cytometry (CyTOF) allowed deep immune phenotyping and analysis of cell cycle progression of Th cells enriched from AS patients in response to GSK-J4 treatment. tdistributed stochastic neighbour embedding (t-SNE) plots ( Figure S4A ) confirm that GSK-J4 has a broad anti-inflammatory effect (36, 37, 40) , highlighting a reduction in TNFα, IL-22 and IL-17
cytokines ( Figure S4B) . Activation markers such as HLA-DR and CD25 were found to be reduced following treatment with GSK-J4, in addition to a reduction in cell proliferation marker Ki-67 ( Figure   S4C ). Interestingly, we observed an upregulation of CXCR3, CCR7 and CD3 surface marker expression following GSK-J4 treatment, suggesting an increase in activated and/or memory T cells ( Figure S4C ) To identify cell cycle clusters, we manually gated based on the expression of phospho-Histone H3 (P-Histone, Ser10), IDU and pRb, representing markers of cell cycle progression (Figure 2F and Figure 2G ). This confirms a reduction in S phase and an increase in cells in G0 phase. Combined, these data suggest that GSK-J4 induces a reversible anergic state in human Th17 cells.
Histone demethylase treatment induces transcriptional changes affecting immune phenotype and metabolism of TH17 cells -To understand the GSK-J4 mediated phenotypic
changes we initially analysed gene expression using bulk RNA sequencing (RNA-seq), performed in CD4 + T cells enriched for 7 days in IL-6, IL-23, and TGF-β, then cultured in the presence of GSK-J4 or DMSO for 24 hours. These data reveal a transcriptional signature that comprises >2200 genes with a significant log2-fold change and with ~58% showing down-regulation ( Figure 3A) . Reactome pathway analysis of differentially regulated genes shows that GSK-J4 impacts on processes comprising metabolic pathways, cell cycle, respiratory chain electron transport, interleukin and cytokine signalling (Figure 3B and Figure S5A ) and in addition shows upregulation of ATF4 and DDIT3, indicating a possible ATF4 mediated stress response. Although ATF4 and DDIT3 (CHOP) are upregulated, confirmed by qPCR ( Figure 3D) , typical downstream metabolic targets including e.g. argininosuccinate synthase (ASS1) or asparagine synthase (ASNS) ( Figure 3C) are not significantly affected. Knockdown of KDM6B but not KDM6A or KDM5B revealed a similar ATF4 transcriptional response ( Figure 3E ) as GSK-J4, confirming that this effect is specifically driven by inhibition of KDM6B histone demethylase activity. Downstream ATF4/DDIT3 effects do not appear to be regulated through the canonical stress-induced eIF2a phosphorylation pathway, since ISRIB (41), a generic inhibitor of the ATF4 mediated integrated stress response (ISR) did not result in cytokine levels similar to control conditions ( Figure 3F ) and possibly explains the lack of induction of classical stress-induced metabolic ATF4 targets.
Next, we examined the global levels of H3K27me3, the KDM6 demethylase substrate, in addition to H3K4me3. We identified substantial global increases in H3K27me3 at transcriptional start sites (TSS) upon GSK-J4 inhibition, consistent with the expected effect of KDM6A/KDM6B as H3K27 demethylases ( Figure 3G) . In line with a large fraction of upregulated genes we also observed global increases in H3K4me3 at TSSs following GSK-J4 treatment (Figure 3H) . The change in H3K27me3 was greater in genes that showed the largest downregulation ( Figure 3I ) supporting a model of PRC mediated gene silencing. However, several upregulated genes such as DDIT3 show inverse patterns such as increased levels of repressive H3K27 marks with reduced H3K4me3 levels
( Figure 3J) , whereas the T-box transcription factor Tbet (TBX21) regulating Tcell functions and being a direct, repressed target of DDIT3 (42), follows a pattern of PRC-mediated silencing with increased H3K27me3 levels and reduced H3K4me3 and transcript levels ( Figure 3K ).
Single-cell transcriptomics reveals distinct populations of inflammatory Tcells following
KDM6 inhibition -The observation of extensive heterogeneity with respect to cell cycle progression (Figure 2) , prompted us to evaluate metabolic or immune gene expression by using single-cell transcriptomics. We initially performed single-cell analysis on PBMC samples cultured in the presence of either DMSO or GSK-J4 and observed a general anti-inflammatory response in all major cell types exposed to GSK-J4 ( Figure S6A) . CD4 + T cells were then isolated from AS patients and enriched for 7 days in IL-6, IL-23 and TGF-β, followed by 24 hours treatment with DMSO or GSK-J4. Single-cell transcriptome analysis was then performed on ~2,000 cells from each donor (n=3 donors) ( Figure 4A ). We identified 9 unique clusters based on their gene expression profiles, comparable across all three patients (Figure 4B , Figure S6B and S6C). Similar to the mass cytometry data, we observed a significant shift in the t-SNE clustering following GSK-J4 treatment, with reduced numbers of cells within clusters 1, 2, 4, 8, 9 and increased numbers of cells within clusters 3, 5, 6 and 7 ( Figure 4B) . Clusters 1 and 3 showed the strongest expression of inflammatory cytokines, such as IFN-γ and IL-17A ( Figure 4C and Figure S6D ), and displayed a strong shift in cell numbers following treatment with GSK-J4. In agreement with our bulk RNA-seq data, we also observed a significant increase in DDIT3 expression following GSK-J4 treatment ( Figure 4D) . We identified discriminatory markers that account for the shift in T cell clustering in response to GSK-J4 for each of the clusters (Figure 4E ). Clusters 1, 4, 8 and 9 were associated with a robust inflammatory signature, with enrichment of cytokines such as IL-26, IL-17A, IL-17F and IFN-γ ( Figure 4C, Figure 4E , Figure S6D ). In contrast, clusters 5 and 7, which are nearly absent in the DMSO treatment, are primarily associated with an increase in cell numbers following GSK-J4 treatment, and show a metallothionein gene enrichment and an ATF4 response ( Figure   S6E and S6F). Clusters 8 and 9 produce high levels of chemokines, with cluster 8 expressing high levels of proliferative markers such as MKI67 (Ki-67) ( Figure S6G ). Cluster 7, which is almost exclusively expressed following GSK-J4 treatment, shows high expression of T cell memory markers, such as PTPRC (CD45) and CCR7, indicating a shift from proliferating or inflammatory cells towards a memory or resting phenotype (Figure 4E and Figure S6H ). To further investigate the complex pattern of T cell differentiation in response to GSK-J4, we performed pseudo-temporal ordering to identify genes that are differentially regulated as a component of T cell differentiation. By using a semi-supervised method, where genes associated with the GO term T cell activation (GO:0042110) we defined the biological trajectory (43). DMSO treated and GSK-J4 treated cells are placed at opposite ends of the pseudotime trajectory ( Figure S7A) , confirming that GSK-J4
treatment leads to a significant reduction in genes associated with T-cell activation. This approach also identified a significant number of genes associated with the TCA cycle and the electron transport chain that were downregulated as a consequence of GSK-J4 treatment (Figure S7B , supplementary data).
GSK-J4 induces metabolic reprogramming in Th17 cells -the observed transcriptomic changes
suggested a link between H3K27 demethylase inhibitor treatment and metabolic perturbations, leading us to investigate in more detail the resulting T cell metabolome. Human CD45RA+ T-cells were isolated from 6 healthy donors, Th17 cells were obtained as described above and treated with DMSO, GSK-J4 and its negative control GSK-J5. Extracts taken at 12 hr and 24 hr timepoints were subjected to an LC/MS based approach. Random Forest comparisons produced predictive accuracies of 83.3% or greater (DMSO vs. GSK-J4 vs. GSK-J5) ( Figure S8A) , which is well above what would be expected from random chance alone (33% for a 3-way comparison). Cellular metabolite changes during the Th17 differentiation process indicated a notable shift towards glucose utilization, increased pentose phosphate pathway metabolism (PPP) and a marked increase in nucleotides, NAD+, FAD and ADP-ribose levels (Figure 5A and Figure S8 and Figure   S9 ). Depletion of several amino acids, cellular ascorbate and a strong signature of membrane lipid biosynthesis, as well as an increase in protein glycosylation pathway activity ( Figure S9 with a consistent set of phenotypes that correlate with subsets of highly inflammatory, memory and resting cells. In agreement with our bulk RNA-seq analysis, KDM6 inhibitor treatment of Th17 cells leads to a significant downregulation in Th17 specific cytokine function and to anti-proliferative effects. This is clearly reflected in the single cell data where significant shifts of highly inflammatory cells following GSK-J4 treatment are observed towards a resting state, suggesting a preferential inhibitor activity on proliferating and inflammatory cells.
Importantly, an effective Th17 cell response requires a T cell to adapt its metabolic state in response to various microenvironments and stimuli. Quiescent T-cell energy demands are low, they primarily oxidise glucose-derived pyruvate in their mitochondria, which ensures optimal ATP production per molecule of glucose (55, 56). Following activation, T cells undergo metabolic reprogramming in order to significantly increase the availability of ATP. These are usually shortlived events that rely primarily on glycolysis for their energy demands (55, 56), which is also observed in cytokine-activated lymphocytes (57). Supporting our observations, an elevated rate of aerobic glycolysis is accompanied by increased expression of glycolytic enzymes and nutrient transporters (58). This increased flux through the glycolytic pathway is controlled by mTORC1 signalling and provides the necessary metabolic precursors for proliferation and effector functions (59).
A conspicuous transcriptional response to GSK-J4 treatment, corroborated by knockdown experiments, is a change in metabolic gene expression. Although we observe a characteristic ATF4 signature in NK cells following GSK-J4 treatment (36), we only observe a robust DDIT3 upregulation in this study with a consistent lack of upregulated metabolic targets, which are otherwise associated with an ATF4-DDIT3 mediated stress response. Importantly, DDIT3 has been shown to directly repress critical Tcell transcription factors like T-bet, leading to reduced cytokine output in tumourinfiltrating Tcells and thus might contribute to the observed anti-inflammatory phenotype (42).
The observed metabolic changes-i.e. upregulated glycolytic and downregulated TCA cycle activity leading to consequent reduction in inflammatory cytokine production and anergy-are best explained by the observed H3K27 mediated silencing of key transcription factors such as MYC, PPARg and PPRC1 as a consequence of GSK-J4 treatment (61). Recently, it has been shown that inhibition of mTORC1 signalling rescues ATF4-deficient cells from MYC-induced endoplasmic reticulum stress (60). This reveals an essential role for ATF4 in survival following MYC activation and our data suggests that KDM demethylases are an important regulator of this pathway.
We postulate that these mitochondria-centered events, i.e. reduced biogenesis and function, and the TCR stimulated increase in glycolytic activity are critical drivers of the observed Th17 phenotype upon demethylase inhibition where anergy is associated with the development of a memory T cell phenotype that leads to downregulation of glutaminolysis and lipid biosynthesis (62). Importantly, the observed mitochondrial impairment upon demethylase inhibition does not show any sign of (65).
Taken together, our results suggest a critical role of KDM6 enzymes in maintaining Th17 functions by controlling metabolic switches, necessary for Tcells to adapt to their specific roles. The results provide a basis for further investigations into using small molecule epigenetic and metabolic inhibitors to understand these critical facets of the adaptive immune system.
MATERIALS and METHODS
Lymphocyte isolation -T cells were isolated from venous blood, obtained from healthy volunteers, or from single-donor platelet pheresis residues from the Oxford National Health Service Blood instructions. Expression levels of each gene were determined by reverse-transcription PCR using specific primers, and mRNA levels in each sample were normalized to the relative quantity of bactin gene expression. All experiments were performed in triplicate. The specific primers used in this study are listed in Table S3 .
Compound inhibitor screens -Following Th cell differentiation, the cells were seeded at 50,000 cells/well in 200 μL of culture medium in 96 well plates. Compounds were dissolved in DMSO at concentrations previously described in Cribbs et al 2018 and diluted to achieve the desired working solutions. Compound effects were compared with cells cultured in 0.1% DMSO alone, whereas wells filled with media served as a background control. Following 24 hours of compound treatment, media was harvested and Enzyme-linked Immunosorbent assay (ELISA) was used to measure cytokine release. Small molecules that were able to modify cytokine expression by a 2-fold change and P < 0.05 were considered as significant.
Locked nucleic acid knockdown experiments -Knockdown experiments were conducted using locked nucleic acids (LNA) antisense oligonucleotides designed and synthesized as described previously (69) Single-cell RNA-seq library preparation -Single-cell capture and reverse transcription (RT) were performed as previously described (71). Cells were loaded into a microfluidics cartridge at a concentration of 310 cells per uL. Cell capture, lysis and reverse transcription were all performed using a Nadia instrument (Dolomite Bio). RT reactions were performed using ChemGene beads also captured in the microfluidic wells. Beads were collected from the device and then cDNA amplification was performed. Prior to PCR, the beads were treated with Exo-I. Following PCR purified cDNA was used as an input for Nextera tagmentation reactions. cDNA library quality was assessed using a TapeStation (Agilent Technologies). All cDNA purification steps were performed using Ampure XP beads (Beckkman). High quality samples were then sequenced on a NextSeq 500 sequencer using a 75 cycle High Output kit (Illumina).
Metabolomic studies -Naive CD4+ T-cells were isolated from 6 human donors and subdivided into Mitochondrial function -T cells were stained with 20 µM CM-H 2 DCFDA, 200 nM or 100 nM TMRE in PBS for 30 minutes at 37°C (5% CO 2 ) to determine ROS production and mitochondrial membrane potential respectively. After staining, cells were washed with PBS and fluorescence was measured using a Beckman Coulter CytoFLEX flow cytometer.
Bulk RNA sequencing analysis -A computational pipeline was written calling scripts from the CGAT toolkit (73, 74) to analyze the next generation sequencing data and (https://github.com/cgatdevelopers/cgat-flow). For bulk RNA-seq experiments, sequencing reads were mapped to the reference human genome sequence (GRCh37 (hg19) assembly) using hisat v0.1.6 (75). To count the reads mapped to individual genes, the program featureCounts v1.4.6 was used (76). Only uniquely mapped reads were used in the counting step. The counts table that was generated was then used for differential expression analysis. Differential gene expression analysis was performed with DESeq2 v1.12.3 within the R statistical framework v3.3.0 (77). To define differentially expressed genes, a threshold of ±2-fold change, and a false discovery rate of <0.05 were used.
Single cell RNA sequencing analysis -Reads were demultiplexed, aligned to the GRCh37 (hg19) assembly reference genome, and filtered; and cell barcodes and UMIs were quantified using dropseq tools (71). Dropseq tools uses STAR (78) for alignment. For each gene, UMI counts of all transcript isoforms are summed to obtain a digital measure of total gene expression. All further filtering was performed with Seurat v2.1, 1998 cells (DMSO) and 1962 (GSK-J4) were identified as good quality and were processed for downstream analyses. Of these cells, 2835 median number of genes were detected, with 430 genes expressed in at least 50% of cells. Briefly, outliers were detected for each quality metric that included cells that expressed a minimum of 50 genes per cell and a mitochondrial content of less than 5%.
Dimensionality reduction and clustering -Full descriptions on the clustering procedure can be found in the monocle2 documentation. Briefly, after QC and filtering, gene expression for each cell was normalised by total transcript count and log transformed. To identify highly variable genes that account for cellular heterogeneity, co-varying genes were reduced using the tSNE reduction method. For unbiased clustering, monocle2 uses density peak clustering. Clusters were then projected onto a tSNE plot. Cluster identification was robust across a range of PCs and resolutions.
Pseudotime ordering -Pseudotime ordering was performed using the monocle package (v2.11.3). To isolate a set of ordering genes that define the progression of T cell activation, using the GO term "T cell activation"; GO:0042110. Next, we reduced data dimensionality using the DDRTree method and ordered cells along the resulting trajectory. Finally, we identified genes that change as a function of the computed pseudotime using the differentialGeneTest function.
A q-value threshold of 0.01 was applied to all differential expression tests in the monocle workflow. Gene expression heat maps were produced using the pheatmap package (v1.0.12). After acquisition, all .fcs files in the experiment were normalised using tools within the Helios software and then uploaded to Cytobank (www.cytobank.org) for all gating and further analysis including using clustering and dimensionality reduction algorithms such as SPADE and viSNE (80).
Statistical analysis -All other statistical analyses were performed with GraphPad Prism7 software.
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